Sobi's partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting

| Source: Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB's (publ ) (Sobi) partner Biogen Idec today announced
that new data from their haemophilia clinical development and research programs
will be presented at the 55th Annual Meeting of the American Society of
Hematology (ASH), taking place in New Orleans, December 7-10. Researchers will
discuss 10 abstracts covering the breadth of the company's comprehensive basic
and clinical research programs. This includes new interim data from Phase 3
studies in paediatric populations evaluating the company's investigational long-
lasting recombinant factor VIII Fc fusion protein candidate for haemophilia A
and factor IX Fc fusion protein candidate for haemophilia B.

The titles of the key presentations are as follows:

Factor VIII Fc fusion protein candidate (ELOCTATE(TM)):
  * Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in
    Pediatric Subjects with Hemophilia A: An Interim Analysis of the Kids A-LONG
    Study - Poster #3609 - Monday, December 9 - 6:00-8:00 PM (CST)
  * Dosing Long-Lasting Recombinant Factor VIII Fc Fusion Protein: Experience in
    the A-LONG Study - Poster #3598 - Monday, December 9 - 6:00-8:00 PM (CST)
  * The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In
    Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion
    Protein - Poster #3590 - Monday, December 9 - 6:00-8:00 PM (CST)

Factor IX Fc fusion protein candidate (ALPROLIX(TM)):
  * Association of Bleeding Tendency with Time Under Target FIX Activity Levels
    in Severe Hemophilia B Patients Treated with Recombinant Factor IX Fc Fusion
    Protein - Poster #2349 - Sunday, December 8 - 6:30-8:30 PM (CST)
  * Pharmacokinetics, Safety and Efficacy of Long-lasting Recombinant Factor IX
    Fc Fusion Protein (rFIXFc) in Adolescent Subjects with Hemophilia B: A
    Subgroup Analysis of the B-LONG Study - Poster #2350 - Sunday, December 8 -
    6:30-8:30 PM (CST)
  * Pharmacokinetics of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in
    Pediatric Subjects with Hemophilia B: An Interim Analysis of the Kids B-LONG
    Study - Poster #3599 - Monday, December 9 - 6:00-8:00 PM (CST)

Hemophilia Health Outcomes Research
  * Psychometric Evaluation of Health-Related Quality of Life Data from the A-
    LONG and B-LONG Hemophilia Clinical Trials - Oral Presentation/Abstract #423
    - Monday, December 9 - 11:00 AM (CST)

- - -

About the Fc Fusion Technology Platform
ELOCTATE and ALPROLIX were developed using Fc fusion technology, which takes
advantage of a naturally occurring pathway that delays the breakdown of IgG1
(protein commonly found in the body) by recycling it back into the bloodstream.
This technology is thought to be responsible for the prolonged time that
ALPROLIX and ELOCTATE circulate in the body. While Fc fusion is an established
technology that has been used for more than 15 years, Biogen Idec is the only
company to apply it in haemophilia.

About Haemophilia
Haemophilia is a rare, inherited disorder in which the ability of a person's
blood to clot is impaired. There are different types of haemophilia depending on
which clotting protein, or factor, is missing or reduced, including haemophilia
A (factor VIII deficiency) and haemophilia B (factor IX deficiency). Haemophilia
A occurs in about one in 5,000 male births annually. Haemophilia B is less
common, accounting for about one in 25,000 male births annually. Both forms of
haemophilia occur more rarely in females.

People with haemophilia can experience bleeding episodes that can cause pain,
irreversible joint damage and life-threatening haemorrhages. Prophylactic
infusions of factor VIII or IX can restore the coagulation process, as well as
reduce or prevent new bleeding episodes. The Medical and Scientific Advisory
Council of the National Haemophilia Foundation recommends prophylaxis as the
optimal therapy for people with severe haemophilia.

About the Biogen Idec and Sobi Collaboration
Biogen Idec and Swedish Orphan Biovitrum (Sobi) are partners in the development
and commercialization of ELOCTATE for haemophilia A and ALPROLIX for haemophilia
B. Biogen Idec leads development, has manufacturing rights, and has
commercialization rights in North America and all other regions excluding the
Sobi territory. Sobi has the right to opt in to assume final development and
commercialization in Europe (including Russia), the Middle East and Northern

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at

About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, haemophilia and autoimmune disorders. Founded in
1978, Biogen Idec is the world's oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the company generates more than $5 billion in annual revenues. For product
labelling, press releases and additional information about the company, please

For more information - not for publication
 Media relations           Investor relations

 Oskar Bosson, Head of     Jörgen Winroth, Vice President, Head of Investor
 Communications            Relations

 T: +46 70 410 71 80       T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

 E:  E: